A Study to Rank Different Dosages of Antigen of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A), Based on Their Immune Response and Safety, When Administered to Healthy Adult Women

NCT02956837 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

406

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus Infections

Interventions

BIOLOGICAL: RSV Vaccine (GSK3003891A) formulation 1
BIOLOGICAL: RSV Vaccine (GSK3003891A) formulation 2
BIOLOGICAL: RSV Vaccine (GSK3003891A) formulation 3
DRUG: Placebo (Formulation buffer S9b)

Sponsor

GlaxoSmithKline